Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

Condition(s) studied

Investigational drug(s) / intervention(s)

RGX-314: AAV8 vector containing a transgene for anti-VEGF Fab

Study summary

This is a prospective, observational study designed to evaluate the long-term safety and efficacy of RGX-314. Eligible participants are those who were previously enrolled in a clinical study in which they received a single subretinal administration of RGX-314 in their study eye. Enrollment of each participant in the current study should occur after the participant has completed either the end of study or early termination visit in the previous (parent) clinical study. Participants will be followed for up to 5 years post-RGX-314 administration (inclusive of the parent study). After enrollment and a 6-month follow-up visit, participants will attend at least annual study visits through the end of the 5-year post-RGX-314 administration follow-up period.

Additionally, an interventional fellow eye treatment substudy will evaluate the safety, efficacy, and immunogenicity of subretinal RGX-314 administration in the fellow eye of participants having bilateral disease who previously received a subretinal injection of RGX-314 in their study eye. Participants who qualify for the substudy will receive subretinal administration of RGX-314 in their fellow eye and complete 13 study visits in a 54-week period. Following completion of the substudy participants will continue in the observational portion of the study for up to 5 years post RGX-314 administration in their fellow eye.

Eligibility

Primary outcome measure(s)

• Incidence of ocular adverse events and any serious adverse events in the study eye — 5 years inclusive of parent study
• Fellow eye substudy: Incidence of ocular adverse events and any serious adverse events in the fellow eye — 54 weeks

Trial sites (9)

More AbbVie trials in the USA

Other trials for the same condition